Clinical Trial Detail

NCT ID NCT01954030
Title Phase 1/2 CTO + Bevacizumab for Recurrent Glioma Post-Bevacizumab Failure
Recruitment Terminated
Gender both
Phase Phase Ib/II
Variant Requirements No
Sponsors Annick Desjardins
Indications

malignant glioma

Therapies

Bevacizumab

Carboxyamidotriazole Orotate

Age Groups: adult

No variant requirements are available.